SRNE · Categories · M&A
SRNE - Mergers and acquisitions
Sorrento Therapeutics Inc. (SRNE) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for SRNE
- Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fortune Bioscience in Response to Increasing Worldwide Demand For COVISTIX™COVISTIX is a highly sensitive and rapid antigen detection test for SARS-CoV-2 and its major variants of concern (VOCs), including the Omicron variant.COVISTIX has an enhanced sensitivity in detecting the Omicron variant with a more than 10-fold lower limit of detection (LoD) as compared to that of the original SAR-CoV-2 strain.COVISTIX has been approved for emergency use and is on the market in Brazil and Mexico, and is CE marked for sale in Europe for professional point-of-care use.In response to increasing product demand, Sorrento has invested and becomes a majority owner with an option to acquire 100% of FortuneBio, a diagnostic product manufacturer with dozens of approved diagnostic pro
- Sorrento Completes Acquisition of Virex Health, Will Commercialize Next-Generation at-Home Diagnostic Testing That Rivals PCR-Level Sensitivity for Daily Covid-19 Tests and Early Cancer DiagnosisVirex Health, Inc. is a Boston, Massachusetts company that has developed a powerful, broadly applicable at-home diagnostic platform ("Virex Technology").Virex Technology, invented and developed by Boston University (BU) Professors Mark Grinstaff and Scott Schaus and Virex scientists, employs widely used electrochemistry found in household diabetes glucometer devices for next generation diagnostics.Virex Technology has demonstrated extremely high sensitivity for multiple biological analytes including COVID-19 virus detection as sensitive as 10 TCID50, rivalling PCR sensitivity.Virex's early liver cancer biomarker test detects a liver cancer biomarker in as little as 2 microliters of blood.Vir
- Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology FranchiseAMONG MULTIPLE CLINICAL- AND PRECLINICAL-STAGE NCE (NEW CHEMICAL ENTITY) COMPOUNDS ACQUIRED, ABIVERTINIB IS AN ANCHORING LATE-STAGE DRUG PRODUCT WITH POSITIVE CLINICAL TRIAL RESULTS IN BOTH NON-SMALL CELL LUNG CANCER (NSCLC) AND B-CELL LYMPHOMA: Abivertinib is potentially one of the most effective clinical-stage dual tyrosine kinase inhibitors (TKI), targeting both mutant epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).Abivertinib is a pyrrolopyrimidine-based irreversible third-generation (3G) EGFR TKI, structurally distinct from all other 3G pyrimidine-based EGFR inhibitors.More than 600 cancer patients have been treated with Abivertinib with a strong safety profi